Home / Guides by goal / Hair growth
Best Peptides for Hair Growth: What the Evidence Shows
Do copper peptides like GHK-Cu or cosmetic peptide serums help hair loss? What small studies show, and the approved treatments that aren't peptides.
The short answer
We found no peptide with strong evidence that it regrows scalp hair. The FDA-approved treatments for hair loss that we reviewed are not peptides: topical minoxidil, oral finasteride for men, and prescription JAK inhibitors for severe alopecia areata. The peptide evidence is a handful of small studies: one eyebrow study of a copper peptide, one trial of a related GHK product without copper in its description, and a few small trials of cosmetic peptides, mostly mixtures.
If your hair loss is sudden or in patches, see a clinician. That can have a medical cause.
On this page
Hair-growth serums are full of peptide claims. The treatments with FDA approval for hair loss are not peptides, and the peptide studies are small, short and often of mixed formulas.
The ranking, by strength of evidence
| Peptide | U.S. status | Strongest evidence |
|---|---|---|
| 1. Topical cosmetic peptides | Limited human data | |
| 2. GHK-Cu | Limited human data |
How do we decide what is “best”?
“Best” means best evidence, not best marketing. We rank by the type of evidence first, then its quality and its result. A rank isn’t a recommendation. See how we rate peptides. For hair, strong evidence would be a randomized, controlled trial on the scalp that measured hair count or thickness over months, in people with the same kind of hair loss, using one clearly identified ingredient. The closest we found is one 22-person trial of a single peptide lotion, below. It is too small to count as strong evidence.
What treatments are FDA-approved for hair loss?
None of these is a peptide. We give them as context, not as a recommendation. Dosing and suitability are for the label and a clinician. Brand names are used only to identify the labels.
| Treatment | What the label says it is for | Limits and warnings on the label |
|---|---|---|
| Minoxidil, applied to the scalp, over the counter | To “regrow hair on the top of the scalp.” The men’s product says “vertex only” | Ask a doctor first if you have heart disease. Stop and ask a doctor for chest pain, rapid heartbeat, dizziness, swelling or sudden weight gain. Don’t use it if hair loss is sudden or in patches, or in children. Labels: men, women |
| Finasteride 1 mg, by mouth | Androgenetic alopecia in men only. The effect reverses within 12 months of stopping | Contraindicated in pregnancy; not indicated in women or children. It lowers PSA and may raise the risk of high-grade prostate cancer. After approval, reports included sexual dysfunction that continued after stopping, depression, suicidal ideation and behavior, and male breast cancer (Propecia label) |
| Baricitinib, ritlecitinib, deuruxolitinib | Severe alopecia areata, an autoimmune disease, not common pattern baldness. Baricitinib is also approved for other uses. | Boxed warning: serious infections, mortality, cancer, major cardiovascular events and blood clots (Olumiant, Litfulo, Leqselvi) |
We did not review other options, such as procedures or other prescription drugs. We read the JAK labels for the indication and boxed warning, not their trials. A compounded topical finasteride is not an approved product: in a page last updated April 22, 2025, FDA alerted health care providers to 32 reports from 2019 to 2024, mostly of events that continued after stopping, and said there was no FDA-approved topical finasteride. These are adverse event reports, and FDA describes the risks as potential.
Does GHK-Cu help hair?
GHK-Cu is a copper-binding peptide and is not an FDA-approved drug. We found no controlled trial of GHK-Cu on scalp hair. Our search of PubMed was limited, and industry studies that are not indexed could exist. What exists:
| Study | Design | People | Result | Limits |
|---|---|---|---|---|
| Bo 2026, GHK-Cu serum | Randomized, double-blind, vehicle-controlled, split-face, on eyebrows | 18 healthy people, 12 weeks | Better hair count and diameter; no serious events | Eyebrows, not scalp, and not baldness. We read the abstract, which gives no figures for the comparison. The publisher calls the series peer-reviewed conference proceedings; we could not verify that. A review says the study did not define the form of GHK-Cu or local exposure |
| Lee 2016, a complex of GHK and 5-aminolevulinic acid | Placebo-controlled | 45 men with hair loss, 6 months | More hairs counted; no difference in length or thickness | Not GHK-Cu. Small groups; the abstract does not say “randomized” |
| Liu 2024 | Mice | — | Better delivery and growth signals | Animal. Its phrase “powerful hair growth promoter” is a claim in the introduction, not a human result |
A study in eyebrows says little about scalp hair loss, which is a different area and population. For GHK-Cu’s regulatory status, which differs by form, see our GHK-Cu guide: the HHS interim policy of Oct. 30, 2026 does not name GHK-Cu.
Do cosmetic peptide serums and lotions help?
The evidence is small and mostly of mixed formulas, so a result cannot be credited to one peptide.
| Product | Design | People | Result | Limits |
|---|---|---|---|---|
| GPIGS lotion, Iwabuchi 2016 | Randomized, double-blind | 22 Japanese men, 4 months | Greater proportion of thick hair (p=0.006); better appearance in photos (p=0.020) | Very small; the proportion is not a hair count; funding not stated, and the first authors work at Shiseido |
| Trifolium plus a biomimetic peptide, Loing 2013 | Randomized, placebo-controlled | 30 | Anagen-to-telogen ratio +46% vs −33% | A mixture; the abstract does not name the peptide; the author listed with an affiliation works at the cosmetic-ingredient company Lucas Meyer Cosmetics; figures are changes from baseline |
| Several popular actives, peptides and others, 2025 review | Review of 24 articles and technical files | — | Results described as “promising” | Small samples, no comparison with standard treatment, hair-loss types not declared, conflicts of interest, mostly combined formulas |
Trials that combine a peptide with platelet-rich plasma do not isolate the peptide, so we do not count them. Our guide to topical cosmetic peptides in skin care explains why single-ingredient results matter.
Why does “regrows hair” matter legally?
According to FDA, a product’s intended use decides whether it is a cosmetic or a drug, and claiming that a product restores hair growth can make it a drug. The law does not require FDA approval before cosmetics are sold. So a serum that “regrows hair” is not only a question of evidence, and we do not repeat that claim as a fact.
Do injectable peptides help hair?
We found no human trial for hair with BPC-157, TB-500 or other injectable peptides, though our search was not exhaustive. FDA flags risks with injectable GHK-Cu, including a risk of immune reactions and limited human data. We do not suggest injection as an option.
What are the risks?
- Peptide serums and lotions: the abstracts above that mention safety reported no serious problems, but the studies are few and short. That is not evidence of long-term safety.
- Approved treatments: see the table above. Each has label warnings that need a clinician’s judgment.
- Pregnancy: finasteride is contraindicated, and both minoxidil labels say it may be harmful if used when pregnant or breast-feeding.
Which claims are not supported?
- “Copper peptides regrow your hair.” We found no controlled trial on the scalp.
- “They work as well as minoxidil.” We found no direct comparison.
- “A study in eyebrows proves it for baldness.” It is a different area and population.
- “No side effects.” The data are insufficient.
- “Topical finasteride is risk-free.” FDA has alerted providers to potential serious risks.
What should you ask your doctor or dermatologist?
- What kind of hair loss do I have, and could something else be causing it?
- Which FDA-approved options fit my situation, and what do their labels warn about?
- If I want to try a peptide product, what would show us it is working, and when should I stop?
- Is a compounded product being suggested? Who makes it?
We do not give doses, and we do not recommend products or sellers.
Frequently asked questions
Do peptides regrow hair?
We found no peptide with strong evidence that it regrows scalp hair.
Does GHK-Cu work for hair loss?
We found no controlled trial of GHK-Cu on scalp hair. One small study of 18 people reported better eyebrow hair count and diameter with a GHK-Cu serum.
What is FDA-approved for hair loss?
The treatments we reviewed are not peptides: topical minoxidil, oral finasteride for men, and JAK inhibitors for severe alopecia areata. Each label has its own limits and warnings.
Is compounded topical finasteride approved?
No. FDA says there is no FDA-approved topical finasteride and has received reports of adverse events with compounded versions.
How did we rank them?
We rank by the type of evidence first, then its quality and its result. If no peptide has good evidence for a goal, we say so.
- Human trialsControlled trials in people, published in a journal, that tested a clinical outcome and showed a benefit. The strongest kind of evidence we report.
- Limited human dataSmall, short or inconclusive human studies, including observational studies, uncontrolled trials and controlled trials that did not show a clinical benefit.
- Animal studiesResults in animals often don’t carry over to people.
- Lab studiesCells or tissue in a dish. An early signal, not an answer.
Sources we checked
- Bo 2026: GHK-Cu serum for eyebrow hair, Procedia Multidisciplinary ResearchJournal. Accessed .
- Pharmaceutics 2026: review of GHK-Cu, eyebrow study (PubMed)PubMed. Accessed .
- Lee 2016: GHK and 5-aminolevulinic acid complex in hair loss (PubMed)PubMed. Accessed .
- Liu 2024: copper peptide delivery for hair growth in mice (PubMed)PubMed. Accessed .
- Iwabuchi 2016: GPIGS lotion in men with hair loss (PubMed)PubMed. Accessed .
- Loing 2013: Trifolium and biomimetic peptide for hair (PubMed)PubMed. Accessed .
- Review of cosmetic hair-growth actives, 2025 (PubMed)PubMed. Accessed .
- Topical minoxidil for men, label (DailyMed)FDA. Accessed .
- Topical minoxidil for women, label (DailyMed)FDA. Accessed .
- Propecia (finasteride 1 mg) prescribing information (DailyMed, rev. 11/2023)FDA. Accessed .
- Olumiant (baricitinib) prescribing information (DailyMed)FDA. Accessed .
- Litfulo (ritlecitinib) prescribing information (DailyMed)FDA. Accessed .
- Leqselvi (deuruxolitinib) prescribing information (DailyMed)FDA. Accessed .
- FDA alert: potential risks of compounded finasteride productsFDA. Accessed .
- FDA: is it a cosmetic, a drug, or both?FDA. Accessed .
- FDA authority over cosmetics: how cosmetics are not FDA-approved, but are FDA-regulatedFDA. Accessed .
- FDA: bulk drug substances that may present significant safety risksFDA. Accessed .
- HHS: Enforcement Discretion Policy, with Appendices A and BOther. Accessed .
- Procapil with PRP vs Redensyl, saw palmetto and biotin with PRP in androgenetic alopecia, Cureus 2023 (PubMed)PubMed. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.